Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Beta Pharma Shanghai
This is a Phase III clinical study, which aims to compare the efficacy and safety of BPI-7711 capsule and gefitinib tablet in the treatment of initially-treated patients with locally advanced or recurrent metastatic with EGFR mutation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed non-small cell lung cancer.
The ECOG score of performance status is 0-1.
Locally advanced or recurrent metastatic NSCLC that has never received systemic treatment.
According to RECIST1.1 criteria, there is at least 1 measurable lesion that has not been previously irradiated.
Prior to enrollment, a central laboratory testing report has confirmed that the tumor has one of two common EGFR mutations positive that are sensitive to EGFR-TKI therapy, accompanied with or not accompanied with other EGFR mutation, with the exception of exon 20 insertion.
You may not be if
Previously received systemic treatment for locally advanced or recurrent metastatic cancer.
Primary T790M mutation-positive patient.
Previous interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring hormonal therapy, or any clinically proven active interstitial lung disease.
Known active infections such as hepatitis B, hepatitis C, and human immunodeficiency virus.
Local radiation therapy is carried out within 1 week; more than 30% bone marrow radiation therapy or extensive radiation therapy is performed within 4 weeks.
≤ 4 weeks from major surgery or ≤ 2 weeks from minor surgery.
